Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 111

Sort by

Sort Order Select

Journal Articles

Novel approaches to identify cellular vulnerabilities in TET2-dependent MDS

Blood (2025) 146 (Supplement 1): 3838.

https://doi.org/10.1182/blood-2025-3838

Published: 2025

Journal Articles

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Arun Arunachalam, Jessica Kerr, Jane Reese, Armin Ghobadi, David Wald, Rimas Orentas, Boro Dropulic, Paolo Caimi, Marcos de Lima, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 567.

https://doi.org/10.1182/blood-2025-567

Published: 2025

Journal Articles

Patient-informed CRISPR screening reveals gene targets to improve CAR T-cell efficacy

Beatriz Coutinho De Oliveira, Meraj Khan, Cassandra Gilmour, Saaurav Bari, Jessica Kerr, Yee Peng Phoon, Joseph Fraietta, Frederic Bushman, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 106.

https://doi.org/10.1182/blood-2025-106

Published: 2025

Journal Articles

Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1945.

https://doi.org/10.1182/blood-2025-1945

Published: 2025

Journal Articles

Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)

Arun Arunachalam, Beatriz Coutinho De Oliveira, Celine Gregoire, Ziran Zhao, Lily Simpson-Heavey, John Molina, Arnon Kater, Fleur Peters, Adrian Wiestner, Jennifer Woyach, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 2322.

https://doi.org/10.1182/blood-2025-2322

Published: 2025

Journal Articles

Safety and efficacy of transposon, BAFF-ligand directed chimeric antigen receptor T cells (LMY-920) with pre-apheresis obinutuzumab for patients with Relapsed/Refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Paolo Caimi, Leland Metheny, Lapo Alinari, Changchun Deng, Matthew Spear, Jeff Liter, Branden Moriarity, Beau Webber, Jennifer Woyach, Brian Hill, J. Joseph Melenhorst

Blood (2025) 146 (Supplement 1): 4177.

https://doi.org/10.1182/blood-2025-4177

Published: 2025

Journal Articles

Signaling role of viral protein motif and its application in CAR T cell therapy

Wooram Jung, Kunho Chung, Jude Franklin, David Wald, J. Joseph Melenhorst, Jae Jung

Blood (2025) 146 (Supplement 1): 5892.

https://doi.org/10.1182/blood-2025-5892

Published: 2025

Journal Articles

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Blood (2024) 144 (Supplement 1): 909.

https://doi.org/10.1182/blood-2024-202659

Published: 2024

Journal Articles

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Benjamin F. Frost, Noelle Frey, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W Loren, Jakub Svoboda, Daniel J. Landsburg, Bruce Levine, Joseph A. Fraietta, J. Joseph Melenhorst, Elizabeth Veloso, Wei-Ting Hwang, Carl H. June, David L. Porter, Saar Gill

Blood (2024) 144 (Supplement 1): 588.

https://doi.org/10.1182/blood-2024-204197

Published: 2024

Journal Articles

Age-Related Cellular Factors Facilitate TET2 Mutant Clonal Hematopoiesis

Daniel J Vail, Dongxu Jiang, Kunho Chung, Yahan Zhang, Sophia Martinez, Luca Guarnera, Yvonne Parker, J. Joseph Melenhorst, Daniel Lindner, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 1278.

https://doi.org/10.1182/blood-2024-211683

Published: 2024

Journal Articles

Metabolic Reprogramming By IDH1 Neomorph Epigenetically Guides CAR T Cell Differentiation

Kunho Chung, Dongxu Jiang, Xiaorong Gu, Jie Xu, Céline Grégoire, Beatriz Coutinho De Oliveira, Babal Kant Jha, J. Joseph Melenhorst

Blood (2024) 144 (Supplement 1): 1035.

https://doi.org/10.1182/blood-2024-205836

Published: 2024

Journal Articles

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Changchun Deng, Paolo F. Caimi, Umar Farooq, Nethrie Idippily, Maria Florencia Giraudo, Jane S. Reese, Sarah Kleinsorge-Block, Daniel Caley, Ryan Stadel, Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David Wald

Blood (2024) 144 (Supplement 1): 94.

https://doi.org/10.1182/blood-2024-206596

Published: 2024

Journal Articles

TET2 Regulates Stability of Mismatch Repair Protein MSH6 and Helps Maintain Genomic Stability Independent of Its Dioxygenase Function

Dongxu Jiang, Yahan Zhang, Xiaorong Gu, Daniel J Vail, Jill Durkin, Simon Schlanger, J. Joseph Melenhorst, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 40.

https://doi.org/10.1182/blood-2024-211171

Published: 2024

Journal Articles

Low Regimen Therapeutic Strategies to Mitigate TET2 Mutant Clonal Hematopoiesis

Dongxu Jiang, Daniel J Vail, Yahan Zhang, Raziullah Khan, Anand Tiwari, Simon Schlanger, Kunho Chung, Cassandra Gilmour, Xiaorong Gu, Yvonne Parker, J. Joseph Melenhorst, Daniel Lindner, Jaroslaw Maciejewski, Babal K. Jha

Blood (2024) 144 (Supplement 1): 2664.

https://doi.org/10.1182/blood-2024-211363

Published: 2024

Journal Articles

Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission

Zhiliang Bai, Bing Feng, Susan E. Mcclory, Caroline Diorio, Ziran Zhao, Li Tang, J. Joseph Melenhorst, Carl June, Stephan Grupp, Rong Fan

Blood (2023) 142 (Supplement 1): 352.

https://doi.org/10.1182/blood-2023-179480

Published: 2023

Journal Articles

Signaling Role of Viral Protein Motif and Its Application in CAR T Cell Therapy

Kunho Chung, Wooram Jung, Jae U Jung, J. Joseph Melenhorst

Blood (2023) 142 (Supplement 1): 4815.

https://doi.org/10.1182/blood-2023-186305

Published: 2023

Journal Articles

Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph

Kunho Chung, Jie Xu, Yaroslav Kaminskiy, Hongxing Sun, Min-Soo Kim, Christopher Petucci, Tong Wang, Rahul M Kohli, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 628–629.

https://doi.org/10.1182/blood-2022-159517

Published: 2022

Journal Articles

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Ziran Zhao, McKensie Collins, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst

Blood (2022) 140 (Supplement 1): 10255–10256.

https://doi.org/10.1182/blood-2022-158614

Published: 2022

Journal Articles

T-Cell Dysfunction in CLL Can be Alleviated By Blocking Sialic Acid-Binding Ig-like Lectin 10 (Siglec-10) Ligation

Jaco A.C. Van Bruggen, Fleur Peters, Joanne M. Rietveld, Gaspard Cretenet, Joseph Melenhorst, Eric Eldering, Arnon P. Kater

Blood (2022) 140 (Supplement 1): 12688–12689.

https://doi.org/10.1182/blood-2022-168800

Published: 2022

Journal Articles

Do CARs finally hit the CLL road?

Arnon P. Kater, J. Joseph Melenhorst

Blood (2022) 139 (12): 1775–1776.

https://doi.org/10.1182/blood.2021014492

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Novel approaches to identify cellular vulnerabilities in TET2-dependent MDS

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Patient-informed CRISPR screening reveals gene targets to improve CAR T-cell efficacy

Pre-manufacturing CD8+ central-memory type 2 T cells predict axicabtagene ciloleucel failure in large B-cell lymphoma

Venetoclax enhances T cell fitness and CAR T-cell manufacturing potential in chronic lymphocytic leukemia (CLL)

Safety and efficacy of transposon, BAFF-ligand directed chimeric antigen receptor T cells (LMY-920) with pre-apheresis obinutuzumab for patients with Relapsed/Refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Signaling role of viral protein motif and its application in CAR T cell therapy

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Age-Related Cellular Factors Facilitate TET2 Mutant Clonal Hematopoiesis

Metabolic Reprogramming By IDH1 Neomorph Epigenetically Guides CAR T Cell Differentiation

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

TET2 Regulates Stability of Mismatch Repair Protein MSH6 and Helps Maintain Genomic Stability Independent of Its Dioxygenase Function

Low Regimen Therapeutic Strategies to Mitigate TET2 Mutant Clonal Hematopoiesis

Single-Cell Multi-Omics Reveals Type-2 Functionality in Maintaining CAR T Cell Longevity Associated with 8-Year Leukemia Remission

Signaling Role of Viral Protein Motif and Its Application in CAR T Cell Therapy

Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph

Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

T-Cell Dysfunction in CLL Can be Alleviated By Blocking Sialic Acid-Binding Ig-like Lectin 10 (Siglec-10) Ligation

Do CARs finally hit the CLL road?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only